Oncologists face burnout from administrative work, but new technology offers solutions to streamline workflows and improve ...

BACKGROUND It has been suggested that cough effectiveness can be improved by assisted techniques. The effects of manually assisted cough and mechanical insufflation on cough flow physiology are ...

Ambience Healthcare becomes the only ambient AI to deliver comprehensive patient context before encounters, extending beyond ...

Patient flow forecasting is a fundamental tool in healthcare and pharmaceutical industries, enabling stakeholders to predict and plan for the treatment requirements of patients accurately.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The future of patient flow forecasting now holds even greater promise with AI-driven drug development and software innovation, improving pharmaceutical forecasters’ capabilities, thus enabling ...

Nodthera Charts Obesity Future With First Patients Dosed In Phase 2 RESOLVE-1 Trial Of Oral NLRP3 Inflammasome Inhibitor NT-0796. Date. 2025-06-04 07:01:26. Share on Facebook; Tweet on Twitter ...

ATLANTA & DALLAS, June 04, 2025--Chart Industries, Inc. (NYSE: GTLS) and Flowserve Corporation (NYSE: FLS) today announced that they have entered into a definitive agreement to combine in an all ...

RESOLVE-1 is a randomized, double-blind, placebo-controlled Phase 2 trial that will evaluate the efficacy and safety of NT-0796 in patients with obesity, with or without type 2 diabetes, over 24 weeks ...

With PAS in place, the hospital expects to serve up to 24 mothers per hour for obstetrics-gynecology services and 10 adolescent patients per hour, improving patient flow and service delivery. To book ...

As executive director of logistics, capacity and patient throughput at Sarasota Memorial Health Care System (SMHCS), I’m privileged to have been part of a major AI-enabled transformation in ...

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Provided by GlobeNewswire Jun 4, 2025, 11:00:00 AM.